APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Microbiome CDMO

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Microbiome CDMO Market Outlook and Growth Opportunities 2026

Report ID 17418853041 January 2026191 pages

Choose your research edition.

Industry ResearchMicrobiome CDMO Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Microbiome CDMO Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Microbiome CDMO Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Microbiome CDMO Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Microbiome CDMO Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Microbiome CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Microbiome CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Microbiome CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Microbiome CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Microbiome CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Microbiome CDMO market include Arranta Bio, Wacker Chemie AG, Bactera, SGS Quay Pharma, Biose, EnteroBiotix, Genome And Company, Lallemand Health Solutions and List Bio, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Microbiome CDMO market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Microbiome CDMO and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Microbiome CDMO revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Microbiome CDMO market.

Microbiome CDMO Segment by Company

Arranta Bio

Wacker Chemie AG

Bactera

SGS Quay Pharma

Biose

EnteroBiotix

Genome And Company

Lallemand Health Solutions

List Bio

Rise BioServices

Lonza

MaaT Pharma

NIZO

Quay Pharmaceuticals

Recipharm

Microbiome CDMO Segment by Type

Microbial CDMO

Antibiotic CDMO

Phage CDMO

Bacteriocins CDMO

Microbiome CDMO Segment by Application

Vaccine R&D

Biopharmaceutical

Cell Therapy

Others

Microbiome CDMO Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Microbiome CDMO status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Microbiome CDMO key companies, revenue, market share, and recent developments.

3. To split the Microbiome CDMO breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Microbiome CDMO market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Microbiome CDMO significant trends, drivers, influence factors in global and regions.

6. To analyze Microbiome CDMO competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microbiome CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Microbiome CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microbiome CDMO.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Microbiome CDMO industry.

Chapter 3: Detailed analysis of Microbiome CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Microbiome CDMO in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Microbiome CDMO in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Microbiome CDMO Industry Trends Table 2. Microbiome CDMO Industry Drivers Table 3. Microbiome CDMO Industry Opportunities and Challenges Table 4. Microbiome CDMO Industry Restraints Table 5. Global Microbiome CDMO Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Microbiome CDMO Revenue Share by Company (2021-2026) Table 7. Global Microbiome CDMO Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Microbiome CDMO Key Company Manufacturing Base & Headquarters Table 9. Global Microbiome CDMO Company, Product Type & Application Table 10. Global Microbiome CDMO Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Microbiome CDMO by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Microbial CDMO Table 15. Significant Companies of Antibiotic CDMO Table 16. Significant Companies of Phage CDMO Table 17. Significant Companies of Bacteriocins CDMO Table 18. Global Microbiome CDMO Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Microbiome CDMO Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Microbiome CDMO Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Microbiome CDMO Sales Value Share by Type (2021-2026) Table 22. Global Microbiome CDMO Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Vaccine R&D Table 24. Significant Companies of Biopharmaceutical Table 25. Significant Companies of Cell Therapy Table 26. Significant Companies of Others Table 27. Global Microbiome CDMO Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Microbiome CDMO Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Microbiome CDMO Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Microbiome CDMO Sales Value Share by Application (2021-2026) Table 31. Global Microbiome CDMO Sales Value Share by Application (2027-2032) Table 32. Global Microbiome CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Microbiome CDMO Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Microbiome CDMO Sales Value Share by Region (2021-2026) Table 35. Global Microbiome CDMO Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Microbiome CDMO Sales Value Share by Region (2027-2032) Table 37. Global Microbiome CDMO Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Microbiome CDMO Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Microbiome CDMO Sales Value Market Share by Country (2021-2026) Table 40. Global Microbiome CDMO Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Microbiome CDMO Sales Value Market Share by Country (2027-2032) Table 42. Arranta Bio Company Information Table 43. Arranta Bio Business Overview Table 44. Arranta Bio Microbiome CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Arranta Bio Microbiome CDMO Product Portfolio Table 46. Arranta Bio Recent Development Table 47. Wacker Chemie AG Company Information Table 48. Wacker Chemie AG Business Overview Table 49. Wacker Chemie AG Microbiome CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Wacker Chemie AG Microbiome CDMO Product Portfolio Table 51. Wacker Chemie AG Recent Development Table 52. Bactera Company Information Table 53. Bactera Business Overview Table 54. Bactera Microbiome CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Bactera Microbiome CDMO Product Portfolio Table 56. Bactera Recent Development Table 57. SGS Quay Pharma Company Information Table 58. SGS Quay Pharma Business Overview Table 59. SGS Quay Pharma Microbiome CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. SGS Quay Pharma Microbiome CDMO Product Portfolio Table 61. SGS Quay Pharma Recent Development Table 62. Biose Company Information Table 63. Biose Business Overview Table 64. Biose Microbiome CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Biose Microbiome CDMO Product Portfolio Table 66. Biose Recent Development Table 67. EnteroBiotix Company Information Table 68. EnteroBiotix Business Overview Table 69. EnteroBiotix Microbiome CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. EnteroBiotix Microbiome CDMO Product Portfolio Table 71. EnteroBiotix Recent Development Table 72. Genome And Company Company Information Table 73. Genome And Company Business Overview Table 74. Genome And Company Microbiome CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Genome And Company Microbiome CDMO Product Portfolio Table 76. Genome And Company Recent Development Table 77. Lallemand Health Solutions Company Information Table 78. Lallemand Health Solutions Business Overview Table 79. Lallemand Health Solutions Microbiome CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Lallemand Health Solutions Microbiome CDMO Product Portfolio Table 81. Lallemand Health Solutions Recent Development Table 82. List Bio Company Information Table 83. List Bio Business Overview Table 84. List Bio Microbiome CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. List Bio Microbiome CDMO Product Portfolio Table 86. List Bio Recent Development Table 87. Rise BioServices Company Information Table 88. Rise BioServices Business Overview Table 89. Rise BioServices Microbiome CDMO Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Rise BioServices Microbiome CDMO Product Portfolio Table 91. Rise BioServices Recent Development Table 92. Lonza Company Information Table 93. Lonza Business Overview Table 94. Lonza Microbiome CDMO Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Lonza Microbiome CDMO Product Portfolio Table 96. Lonza Recent Development Table 97. MaaT Pharma Company Information Table 98. MaaT Pharma Business Overview Table 99. MaaT Pharma Microbiome CDMO Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. MaaT Pharma Microbiome CDMO Product Portfolio Table 101. MaaT Pharma Recent Development Table 102. NIZO Company Information Table 103. NIZO Business Overview Table 104. NIZO Microbiome CDMO Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. NIZO Microbiome CDMO Product Portfolio Table 106. NIZO Recent Development Table 107. Quay Pharmaceuticals Company Information Table 108. Quay Pharmaceuticals Business Overview Table 109. Quay Pharmaceuticals Microbiome CDMO Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Quay Pharmaceuticals Microbiome CDMO Product Portfolio Table 111. Quay Pharmaceuticals Recent Development Table 112. Recipharm Company Information Table 113. Recipharm Business Overview Table 114. Recipharm Microbiome CDMO Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Recipharm Microbiome CDMO Product Portfolio Table 116. Recipharm Recent Development Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Microbiome CDMO Product Image Figure 2. Global Microbiome CDMO Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Microbiome CDMO Market Size (2021-2032) & (US$ Million) Figure 4. Global Microbiome CDMO Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Microbial CDMO Image Figure 8. Antibiotic CDMO Image Figure 9. Phage CDMO Image Figure 10. Bacteriocins CDMO Image Figure 11. Global Microbiome CDMO Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Microbiome CDMO Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Microbiome CDMO Sales Value Share by Type (2021-2032) Figure 14. Vaccine R&D Image Figure 15. Biopharmaceutical Image Figure 16. Cell Therapy Image Figure 17. Others Image Figure 18. Global Microbiome CDMO Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Microbiome CDMO Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Microbiome CDMO Sales Value Share by Application (2021-2032) Figure 21. Global Microbiome CDMO Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Microbiome CDMO Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Microbiome CDMO Sales Value (2021-2032) & (US$ Million) Figure 24. North America Microbiome CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Microbiome CDMO Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Microbiome CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Microbiome CDMO Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Microbiome CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Microbiome CDMO Sales Value (2021-2032) & (US$ Million) Figure 30. South America Microbiome CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Microbiome CDMO Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Microbiome CDMO Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Microbiome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Microbiome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Microbiome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Microbiome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Microbiome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Microbiome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Microbiome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Microbiome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Microbiome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Microbiome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Microbiome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Microbiome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Microbiome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Microbiome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Microbiome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Microbiome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Microbiome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Microbiome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Microbiome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Microbiome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Microbiome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Microbiome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Microbiome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Microbiome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Microbiome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Microbiome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Microbiome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Microbiome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Microbiome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Microbiome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Microbiome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Microbiome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Microbiome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Microbiome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Microbiome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Microbiome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Microbiome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Microbiome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Microbiome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Microbiome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Microbiome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Microbiome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Microbiome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Microbiome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Microbiome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Microbiome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Microbiome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Microbiome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Microbiome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Microbiome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Microbiome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Microbiome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Microbiome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Microbiome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Microbiome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Microbiome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Microbiome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Microbiome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Microbiome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Microbiome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Microbiome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Microbiome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Microbiome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Microbiome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Microbiome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Microbiome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Microbiome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Microbiome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Microbiome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Microbiome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Microbiome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Microbiome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Microbiome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Microbiome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Microbiome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Microbiome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Microbiome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Microbiome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Microbiome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Microbiome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Microbiome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Microbiome CDMO Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Microbiome CDMO Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Microbiome CDMO Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Microbial CDMO
  • Antibiotic CDMO
  • Phage CDMO
  • Bacteriocins CDMO
Applications
  • Vaccine R&D
  • Biopharmaceutical
  • Cell Therapy
  • Others
Companies covered
  • Arranta Bio
  • Wacker Chemie AG
  • Bactera
  • SGS Quay Pharma
  • Biose
  • EnteroBiotix
  • Genome And Company
  • Lallemand Health Solutions
  • List Bio
  • Rise BioServices
  • Lonza
  • MaaT Pharma
  • NIZO
  • Quay Pharmaceuticals
  • Recipharm

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Microbiome CDMO Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Microbiome CDMO Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Microbiome CDMO Market Dynamics
  1. 2.1 Microbiome CDMO Industry Trends
  2. 2.2 Microbiome CDMO Industry Drivers
  3. 2.3 Microbiome CDMO Industry Opportunities and Challenges
  4. 2.4 Microbiome CDMO Industry Restraints
3 Microbiome CDMO Market by Company
  1. 3.1 Global Microbiome CDMO Company Revenue Ranking in 2025
  2. 3.2 Global Microbiome CDMO Revenue by Company (2021-2026)
  3. 3.3 Global Microbiome CDMO Company Ranking (2024-2026)
  4. 3.4 Global Microbiome CDMO Company Manufacturing Base and Headquarters
  5. 3.5 Global Microbiome CDMO Company Product Type and Application
  6. 3.6 Global Microbiome CDMO Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Microbiome CDMO Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Microbiome CDMO Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Microbiome CDMO Market by Type
  1. 4.1 Microbiome CDMO Type Introduction
  2. 4.1.1 Microbial CDMO
  3. 4.1.2 Antibiotic CDMO
  4. 4.1.3 Phage CDMO
  5. 4.1.4 Bacteriocins CDMO
  6. 4.2 Global Microbiome CDMO Sales Value by Type
  7. 4.2.1 Global Microbiome CDMO Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Microbiome CDMO Sales Value by Type (2021-2032)
  9. 4.2.3 Global Microbiome CDMO Sales Value Share by Type (2021-2032)
5 Microbiome CDMO Market by Application
  1. 5.1 Microbiome CDMO Application Introduction
  2. 5.1.1 Vaccine R&D
  3. 5.1.2 Biopharmaceutical
  4. 5.1.3 Cell Therapy
  5. 5.1.4 Others
  6. 5.2 Global Microbiome CDMO Sales Value by Application
  7. 5.2.1 Global Microbiome CDMO Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Microbiome CDMO Sales Value by Application (2021-2032)
  9. 5.2.3 Global Microbiome CDMO Sales Value Share by Application (2021-2032)
6 Microbiome CDMO Regional Value Analysis
  1. 6.1 Global Microbiome CDMO Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Microbiome CDMO Sales Value by Region (2021-2032)
  3. 6.2.1 Global Microbiome CDMO Sales Value by Region: 2021-2026
  4. 6.2.2 Global Microbiome CDMO Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Microbiome CDMO Sales Value (2021-2032)
  7. 6.3.2 North America Microbiome CDMO Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Microbiome CDMO Sales Value (2021-2032)
  10. 6.4.2 Europe Microbiome CDMO Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Microbiome CDMO Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Microbiome CDMO Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Microbiome CDMO Sales Value (2021-2032)
  16. 6.6.2 South America Microbiome CDMO Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Microbiome CDMO Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Microbiome CDMO Sales Value Share by Country, 2025 VS 2032
7 Microbiome CDMO Country-level Value Analysis
  1. 7.1 Global Microbiome CDMO Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Microbiome CDMO Sales Value by Country (2021-2032)
  3. 7.2.1 Global Microbiome CDMO Sales Value by Country (2021-2026)
  4. 7.2.2 Global Microbiome CDMO Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Microbiome CDMO Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Microbiome CDMO Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Microbiome CDMO Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Microbiome CDMO Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Microbiome CDMO Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Microbiome CDMO Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Microbiome CDMO Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Microbiome CDMO Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Microbiome CDMO Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Microbiome CDMO Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Microbiome CDMO Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Microbiome CDMO Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Microbiome CDMO Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Microbiome CDMO Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Microbiome CDMO Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Microbiome CDMO Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Microbiome CDMO Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Microbiome CDMO Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Microbiome CDMO Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Microbiome CDMO Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Microbiome CDMO Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Microbiome CDMO Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Microbiome CDMO Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Microbiome CDMO Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Microbiome CDMO Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Microbiome CDMO Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Microbiome CDMO Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Microbiome CDMO Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Microbiome CDMO Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Microbiome CDMO Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Microbiome CDMO Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Microbiome CDMO Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Microbiome CDMO Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Microbiome CDMO Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Microbiome CDMO Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Microbiome CDMO Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Microbiome CDMO Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Microbiome CDMO Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Microbiome CDMO Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Microbiome CDMO Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Microbiome CDMO Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Microbiome CDMO Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Microbiome CDMO Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Microbiome CDMO Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Microbiome CDMO Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Microbiome CDMO Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Microbiome CDMO Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Microbiome CDMO Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Microbiome CDMO Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Microbiome CDMO Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Microbiome CDMO Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Microbiome CDMO Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Microbiome CDMO Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Microbiome CDMO Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Microbiome CDMO Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Microbiome CDMO Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Microbiome CDMO Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Microbiome CDMO Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Microbiome CDMO Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Microbiome CDMO Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Microbiome CDMO Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Microbiome CDMO Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Microbiome CDMO Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Microbiome CDMO Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Microbiome CDMO Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Microbiome CDMO Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Microbiome CDMO Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Microbiome CDMO Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Microbiome CDMO Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Microbiome CDMO Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Microbiome CDMO Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Microbiome CDMO Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Microbiome CDMO Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Microbiome CDMO Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Microbiome CDMO Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Microbiome CDMO Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Microbiome CDMO Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Microbiome CDMO Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Microbiome CDMO Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Microbiome CDMO Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Microbiome CDMO Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Microbiome CDMO Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Microbiome CDMO Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Microbiome CDMO Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Arranta Bio
  2. 8.1.1 Arranta Bio Company Information
  3. 8.1.2 Arranta Bio Business Overview
  4. 8.1.3 Arranta Bio Microbiome CDMO Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Arranta Bio Microbiome CDMO Product Portfolio
  6. 8.1.5 Arranta Bio Recent Developments
  7. 8.2 Wacker Chemie AG
  8. 8.2.1 Wacker Chemie AG Company Information
  9. 8.2.2 Wacker Chemie AG Business Overview
  10. 8.2.3 Wacker Chemie AG Microbiome CDMO Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Wacker Chemie AG Microbiome CDMO Product Portfolio
  12. 8.2.5 Wacker Chemie AG Recent Developments
  13. 8.3 Bactera
  14. 8.3.1 Bactera Company Information
  15. 8.3.2 Bactera Business Overview
  16. 8.3.3 Bactera Microbiome CDMO Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bactera Microbiome CDMO Product Portfolio
  18. 8.3.5 Bactera Recent Developments
  19. 8.4 SGS Quay Pharma
  20. 8.4.1 SGS Quay Pharma Company Information
  21. 8.4.2 SGS Quay Pharma Business Overview
  22. 8.4.3 SGS Quay Pharma Microbiome CDMO Revenue and Gross Margin (2021-2026)
  23. 8.4.4 SGS Quay Pharma Microbiome CDMO Product Portfolio
  24. 8.4.5 SGS Quay Pharma Recent Developments
  25. 8.5 Biose
  26. 8.5.1 Biose Company Information
  27. 8.5.2 Biose Business Overview
  28. 8.5.3 Biose Microbiome CDMO Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Biose Microbiome CDMO Product Portfolio
  30. 8.5.5 Biose Recent Developments
  31. 8.6 EnteroBiotix
  32. 8.6.1 EnteroBiotix Company Information
  33. 8.6.2 EnteroBiotix Business Overview
  34. 8.6.3 EnteroBiotix Microbiome CDMO Revenue and Gross Margin (2021-2026)
  35. 8.6.4 EnteroBiotix Microbiome CDMO Product Portfolio
  36. 8.6.5 EnteroBiotix Recent Developments
  37. 8.7 Genome And Company
  38. 8.7.1 Genome And Company Company Information
  39. 8.7.2 Genome And Company Business Overview
  40. 8.7.3 Genome And Company Microbiome CDMO Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Genome And Company Microbiome CDMO Product Portfolio
  42. 8.7.5 Genome And Company Recent Developments
  43. 8.8 Lallemand Health Solutions
  44. 8.8.1 Lallemand Health Solutions Company Information
  45. 8.8.2 Lallemand Health Solutions Business Overview
  46. 8.8.3 Lallemand Health Solutions Microbiome CDMO Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Lallemand Health Solutions Microbiome CDMO Product Portfolio
  48. 8.8.5 Lallemand Health Solutions Recent Developments
  49. 8.9 List Bio
  50. 8.9.1 List Bio Company Information
  51. 8.9.2 List Bio Business Overview
  52. 8.9.3 List Bio Microbiome CDMO Revenue and Gross Margin (2021-2026)
  53. 8.9.4 List Bio Microbiome CDMO Product Portfolio
  54. 8.9.5 List Bio Recent Developments
  55. 8.10 Rise BioServices
  56. 8.10.1 Rise BioServices Company Information
  57. 8.10.2 Rise BioServices Business Overview
  58. 8.10.3 Rise BioServices Microbiome CDMO Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Rise BioServices Microbiome CDMO Product Portfolio
  60. 8.10.5 Rise BioServices Recent Developments
  61. 8.11 Lonza
  62. 8.11.1 Lonza Company Information
  63. 8.11.2 Lonza Business Overview
  64. 8.11.3 Lonza Microbiome CDMO Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Lonza Microbiome CDMO Product Portfolio
  66. 8.11.5 Lonza Recent Developments
  67. 8.12 MaaT Pharma
  68. 8.12.1 MaaT Pharma Company Information
  69. 8.12.2 MaaT Pharma Business Overview
  70. 8.12.3 MaaT Pharma Microbiome CDMO Revenue and Gross Margin (2021-2026)
  71. 8.12.4 MaaT Pharma Microbiome CDMO Product Portfolio
  72. 8.12.5 MaaT Pharma Recent Developments
  73. 8.13 NIZO
  74. 8.13.1 NIZO Company Information
  75. 8.13.2 NIZO Business Overview
  76. 8.13.3 NIZO Microbiome CDMO Revenue and Gross Margin (2021-2026)
  77. 8.13.4 NIZO Microbiome CDMO Product Portfolio
  78. 8.13.5 NIZO Recent Developments
  79. 8.14 Quay Pharmaceuticals
  80. 8.14.1 Quay Pharmaceuticals Company Information
  81. 8.14.2 Quay Pharmaceuticals Business Overview
  82. 8.14.3 Quay Pharmaceuticals Microbiome CDMO Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Quay Pharmaceuticals Microbiome CDMO Product Portfolio
  84. 8.14.5 Quay Pharmaceuticals Recent Developments
  85. 8.15 Recipharm
  86. 8.15.1 Recipharm Company Information
  87. 8.15.2 Recipharm Business Overview
  88. 8.15.3 Recipharm Microbiome CDMO Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Recipharm Microbiome CDMO Product Portfolio
  90. 8.15.5 Recipharm Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst